US Patent 10160811 Treatment with anti-ErbB2 antibodies

Is a

Patent

Patent attributes

Patent Applicant

Genentech

Current Assignee

Genentech

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

101608110

Patent Inventor Names

Steven Shak0

Sharon A. Baughman0

Date of Patent

December 25, 2018

Patent Application Number

140736590

Date Filed

November 6, 2013

Patent Citations Received

‌

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 11655305 Treatment of metastatic breast cancer

‌

US Patent 11414498 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

‌

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

‌

US Patent 11459399 Pharmaceutical compositions of a HER2/neu antibody and use of the same

‌

US Patent 10280228 Treatment with anti-ErbB2 antibodies

‌

US Patent 10689457 Treatment of metastatic breast cancer

...

Patent Primary Examiner

‌

Ilia I Ouspenski

Patent abstract

The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 10160811 Treatment with anti-ErbB2 antibodies

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 10160811 Treatment with anti-ErbB2 antibodies